Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:33:38.668Z.
Calculation as of: 2026-10-06T16:33:38.668Z.
Quote observation: 2026-10-06T16:30:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2ce25f957fe83095360266a8eba44a0c9f304ca71e6017df3a9cc6b1c586d311
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
MapLight Therapeutics, Inc.
Market Cap
$396.99M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$386.53M
Price/FCF Ratio
N/A
TTM Avg
1258.06
3Y Avg
1258.06
5Y Avg
226.77
Market Cap
$384.83M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$410.85M
Price/FCF Ratio
N/A
TTM Avg
4285.33
3Y Avg
985.66
5Y Avg
501.76
Market Cap
$411.29M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $396.99M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $390.83M | N/A | 9.15 | 9.15 | 84.80 |
| Carlsmed, Inc. (CARL)vs › | $404.72M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $386.53M | N/A | 1258.06 | 1258.06 | 226.77 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $384.83M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $410.80M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $410.85M | N/A | 4285.33 | 985.66 | 501.76 |
| Shoulder Innovations, Inc. (SI)vs › | $411.45M | N/A | N/A | N/A | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $411.29M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $379.66M | N/A | 25.86 | 25.37 | 25.37 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
